Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Insulet shares rise as investors focus on Omnipod 5 software upgrade and expanded CGM compatibility

None

Insulet Corporation (PODD) is up 3.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The move higher appears tied to renewed enthusiasm around Insulet’s Omnipod 5 product roadmap after the company announced a U.S. rollout of algorithm enhancements and broader continuous glucose monitor (CGM) compatibility. With the ADA Scientific Sessions starting June 5, investors may also be positioning for incremental clinical and product detail that could support adoption and competitive positioning.

Details:

  • Insulet announced a U.S. rollout of Omnipod 5 algorithm enhancements delivered via an over-the-air software update through the controller or mobile app, with feature access expanding as compatible Pods become available.
  • The same update cycle expands Omnipod 5 compatibility to Abbott’s FreeStyle Libre 3 Plus sensor, a potential adoption tailwind by widening CGM choice for users.
  • Insulet indicated additional information would be shared during the American Diabetes Association (ADA) 86th Scientific Sessions running June 5–8, 2026, which can act as a near-term catalyst for attention on diabetes technology names.
  • This could also reflect a “relief” move after recent attention on a voluntary medical device correction for certain Omnipod Pod lots, with today’s trading emphasizing forward product improvements instead of manufacturing risk.
  • Sources:

    Business Wire, Insulet Investor Relations, FDA

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $PODD Insider Trading Activity

    PODD Insider Trades

    $PODD insiders have traded $PODD stock on the open market 7 times in the past 6 months. Of those trades, 5 have been purchases and 2 have been sales.

    Here’s a breakdown of recent trading of $PODD stock by insiders over the last 6 months:

    • ASHLEY MCEVOY (President and CEO) purchased 4,300 shares for an estimated $1,029,205
    • TIMOTHY C. STONESIFER has made 2 purchases buying 3,752 shares for an estimated $700,277 and 0 sales.
    • WAYNE A.I. FREDERICK sold 1,851 shares for an estimated $542,509
    • MICHAEL R MINOGUE purchased 2,030 shares for an estimated $499,846
    • ELIZABETH H WEATHERMAN purchased 3,450 shares for an estimated $497,489
    • LUCIANA BORIO sold 418 shares for an estimated $59,886

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    $PODD Hedge Fund Activity

    We have seen 405 institutional investors add shares of $PODD stock to their portfolio, and 453 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $PODD Congressional Stock Trading

    Members of Congress have traded $PODD stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

    Here’s a breakdown of recent trading of $PODD stock by members of Congress over the last 6 months:

    • SENATOR TINA SMITH has traded it 2 times. They made 0 purchases and 2 sales worth up to $500,000 on 05/07, 04/29.

    To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

    $PODD Analyst Ratings

    Wall Street analysts have issued reports on $PODD in the last several months. We have seen 3 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

    Here are some recent analyst ratings:

    • William Blair issued a "Outperform" rating on 05/20/2026
    • JP Morgan issued a "Overweight" rating on 05/07/2026
    • Barclays issued a "Underweight" rating on 01/12/2026
    • Truist Securities issued a "Buy" rating on 12/18/2025

    To track analyst ratings and price targets for $PODD, check out Quiver Quantitative's $PODD forecast page.

    $PODD Price Targets

    Multiple analysts have issued price targets for $PODD recently. We have seen 17 analysts offer price targets for $PODD in the last 6 months, with a median target of $249.0.

    Here are some recent targets:

    • Joanne Wuensch from Citigroup set a target price of $165.0 on 05/28/2026
    • Shagun Singh from RBC Capital set a target price of $280.0 on 05/27/2026
    • Marie Thibault from BTIG set a target price of $235.0 on 05/27/2026
    • Travis Steed from B of A Securities set a target price of $208.0 on 05/18/2026
    • Matt Miksic from Barclays set a target price of $198.0 on 05/08/2026
    • Lawrence Biegelsen from Wells Fargo set a target price of $255.0 on 05/07/2026
    • William Plovanic from Canaccord Genuity set a target price of $249.0 on 05/07/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Add Quiver Quantitative to your preferred sources on Google Google News Logo

    Suggested Articles